Compare Suven Life Sciences with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES ELDER PHARMA SUVEN LIFE SCIENCES/
ELDER PHARMA
 
P/E (TTM) x -88.0 -0.2 - View Chart
P/BV x 1.4 0.1 1,368.1% View Chart
Dividend Yield % 1.7 0.0 -  

Financials

 SUVEN LIFE SCIENCES   ELDER PHARMA
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
ELDER PHARMA
Jun-14
SUVEN LIFE SCIENCES/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs338380 88.9%   
Low Rs169188 90.1%   
Sales per share (Unadj.) Rs52.1491.2 10.6%  
Earnings per share (Unadj.) Rs6.8-3.2 -214.7%  
Cash flow per share (Unadj.) Rs8.614.4 59.5%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.3376.5 17.3%  
Shares outstanding (eoy) m127.2820.54 619.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.90.6 841.2%   
Avg P/E ratio x37.1-89.3 -41.6%  
P/CF ratio (eoy) x29.619.7 150.1%  
Price / Book Value ratio x3.90.8 514.9%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,2725,833 553.2%   
No. of employees `0001.1NA-   
Total wages/salary Rs m6612,179 30.3%   
Avg. sales/employee Rs Th6,132.2NM-  
Avg. wages/employee Rs Th611.1NM-  
Avg. net profit/employee Rs Th803.5NM-  
INCOME DATA
Net Sales Rs m6,63510,089 65.8%  
Other income Rs m242257 94.4%   
Total revenues Rs m6,87710,346 66.5%   
Gross profit Rs m1,604-792 -202.6%  
Depreciation Rs m221361 61.3%   
Interest Rs m382,756 1.4%   
Profit before tax Rs m1,587-3,653 -43.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m718125 573.7%   
Profit after tax Rs m869-65 -1,330.4%  
Gross profit margin %24.2-7.8 -308.0%  
Effective tax rate %45.2-3.4 -1,320.2%   
Net profit margin %13.1-0.6 -2,023.0%  
BALANCE SHEET DATA
Current assets Rs m6,2329,240 67.4%   
Current liabilities Rs m1,4909,998 14.9%   
Net working cap to sales %71.5-7.5 -951.7%  
Current ratio x4.20.9 452.5%  
Inventory Days Days8646 186.6%  
Debtors Days Days8360 137.8%  
Net fixed assets Rs m4,04310,124 39.9%   
Share capital Rs m127206 61.9%   
"Free" reserves Rs m8,1835,582 146.6%   
Net worth Rs m8,3107,734 107.5%   
Long term debt Rs m184,889 0.4%   
Total assets Rs m10,38922,882 45.4%  
Interest coverage x43.1-0.3 -13,251.5%   
Debt to equity ratio x00.6 0.3%  
Sales to assets ratio x0.60.4 144.8%   
Return on assets %8.711.8 74.2%  
Return on equity %10.5-0.8 -1,238.1%  
Return on capital %19.522.3 87.5%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m5,622307 1,833.6%   
Fx outflow Rs m1,799125 1,436.1%   
Net fx Rs m3,822181 2,108.3%   
CASH FLOW
From Operations Rs m35611,754 3.0%  
From Investments Rs m-279-561 49.7%  
From Financial Activity Rs m-225-6,762 3.3%  
Net Cashflow Rs m-1484,432 -3.3%  

Share Holding

Indian Promoters % 63.4 39.6 160.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 0.0 16.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 36.1 101.1%  
Shareholders   37,287 16,479 226.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON   

Compare SUVEN LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Apr 20, 2021 (Close)

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS